Novartis is offering a $250,000 prize to fund development of pioneering innovation with great potential in advancing Assistive Tech for Multiple Sclerosis. Applications will be accepted until January 10, 2020, and the winners will be announced during a panel discussion among experts in the field at SXSW in Austin, TX.
This study involved 4,717 participants from two different community-based cohorts. A meta-analysis of both cohorts showed that elevated sCD14 was associated with a 12 percent increased risk of dementia as people got older. Higher levels of sCD14 were also associated with accelerated brain aging in both cohorts, a faster progression of age-related brain atrophy, and a more rapid decline of executive functions.
The authors sum up their findings: “sCD14 is an inflammatory marker related to brain atrophy, cognitive decline, and incident dementia.”
“Higher levels of sCD14 were associated with markers of brain aging and injury, such as total brain atrophy and a decline in executive functioning—the decision-making needed for many activities of daily life,” first author Matthew Pase, of the Florey Institute for Neuroscience and Mental Health in Melbourne, Australia, said in a news release.
Scientists have developed a new gene-therapy technique by transforming human cells into mass producers of tiny nano-sized particles full of genetic material that has the potential to reverse disease processes.
Though the research was intended as a proof of concept, the experimental therapy slowed tumor growth and prolonged survival in mice with gliomas, which constitute about 80 percent of malignant brain tumors in humans.
The technique takes advantage of exosomes, fluid-filled sacs that cells release as a way to communicate with other cells.
Optogenetics, a tool for controlling neurons with light, has given neuroscientists the ability to flip brain cells on and off more or less at will, revolutionizing neuroscience.
Yet the technique faces a fundamental challenge: To study all but the outermost part of the brain, researchers need to implant fiber optics or other invasive devices to deliver light deep into the brain.
Now, in Proceedings of the National Academy of Sciences, Stanford researchers report that they’ve found a less invasive way to do so: injectable nanoparticles that convert sound waves, which can easily penetrate into the brain, into light.
Researchers at Baylor College of Medicine report today in the journal Neuron evidence that refutes the link between increased levels of herpes virus and Alzheimer’s disease. In addition, the researchers provide a new statistical and computational framework for the analysis of large-scale sequencing data.
About 50 million people worldwide are affected by Alzheimer’s disease, a type of progressive dementia that results in the loss of memory, cognitive abilities and verbal skills, and the numbers are growing rapidly. Currently available medications temporarily ease the symptoms or slow the rate of decline, which maximizes the time patients can live and function independently. However, there are no treatments to halt progression of Alzheimer’s disease.
“Like all types of dementia, Alzheimer’s disease is characterized by massive death of brain cells, the neurons. Identifying the reason why neurons begin and continue to die in the brains of Alzheimer’s disease patients is an active area of research,” said corresponding author Dr. Zhandong Liu, associate professor of pediatrics at Baylor and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital.